|
Protocol Number:
01-DK-0247
- Title:
Treatment of Chronic Delta Hepatitis with Pegylated Interferon
- Number:
01-DK-0247
- Summary:
This study will evaluate the safety and effectiveness of a long-acting form of alpha interferon called pegylated interferon in treating hepatitis D virus (HDV) infection. HDV only infects people who already have hepatitis B infection. HDV is often severe and progressive. Alpha interferon is the standard treatment for HDV, given by injection once a day or three times a week for up to 12 months. However, this treatment does not work for everyone, and those who respond usually relapse when the drug is stopped. The sustained-release form of the drug, pegylated interferon, is given just once a week. Pegylated interferon is more effective than standard interferon in hepatitis C patients, with patients experiencing longer-term improvement. This study will evaluate the effects of pegylated interferon on hepatitis D and hepatitis B. It will determine whether long-term therapy with this drug improves inflammation and scarring of the liver, thereby delaying or reversing cirrhosis, and whether the improvement can be maintained.
Patients with chronic hepatitis D over 6 years old may be eligible for this study. Participants will have a medical evaluation, including a history and physical examination, blood tests, routine urinalysis and 24-hour urine collection. Chest X-ray, electrocardiogram, abdominal ultrasound and liver biopsy will be done if these tests have not been done within the last year. In addition, depending on their age and individual health status, some patients may have exercise stress testing, an eye examination, hearing test, and psychiatric consultation. All patients will fill out a health-related quality of life questionnaire.
Patients will receive pegylated interferon by injection once a week and have blood tests to measure the effects of treatment on the liver and on HBV and HDV levels. The medical examination and liver biopsy will be repeated at the end of 12 months. Patients who improved with treatment may continue therapy long-term. Medical evaluations and liver biopsies will be repeated at 3 years and at 5 years.
- Sponsoring Institute:
-
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Recruitment Detail
- Type:
No longer recruiting/follow-up only
- Gender:
Male & Female
- Referral Letter Required:
No
- Population Exclusion(s):
Children
- Eligibility Criteria:
This study is not currently recruiting new subjects. If you have questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.
- Special Instructions:
Currently Not Provided
- Keyword(s):
-
Cirrhosis
-
Chronic Hepatitis
-
Alpha Interferon
-
Hepatitis D Virus
-
Delta Hepatitis
-
Viral Hepatitis
-
Antiviral Agents
- Recruitment Keyword(s):
-
Viral Hepatitis
-
Hepatitis D
-
HDV
-
Delta Hepatitis
-
Liver
-
Hepatitis
- Condition(s):
-
Hepatitis D
- Investigational Drug(s):
-
Peginterferon Alpha-2a
- Investigational Device(s):
- None
- Interventions:
-
Drug: Peginterferon Alpha-2a
- Supporting Site:
-
National Institute of Diabetes and Digestive and Kidney Diseases
- Contact(s):
-
This study is not currently recruiting new subjects. If you have questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.
- Citation(s):
-
Role of hepatitis delta virus infection in hepatocellular carcinoma
-
Hepatitis delta virus as a global health problem
-
Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen An active and progressive disease unresponsive to immunosuppressive treatment
If you have:
Search The Studies | Help | Questions | Clinical Center Home | NIH Home
National Institutes of Health Clinical Center
Bethesda, Maryland 20892. Last update: 05/05/2009
|
|